Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at HC Wainwright

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $42.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 412.82% from the company’s previous close.

Separately, D. Boral Capital reissued a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Monday.

Anavex Life Sciences Trading Down 1.3 %

Shares of AVXL stock opened at $8.19 on Monday. The firm has a market capitalization of $696.67 million, a P/E ratio of -14.89 and a beta of 0.80. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $14.44. The firm’s fifty day simple moving average is $8.84 and its 200 day simple moving average is $8.43.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Equities research analysts anticipate that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.

Institutional Trading of Anavex Life Sciences

Several institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP bought a new position in shares of Anavex Life Sciences during the fourth quarter valued at $1,704,000. Wealth Enhancement Advisory Services LLC increased its position in shares of Anavex Life Sciences by 69.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 26,673 shares of the biotechnology company’s stock worth $286,000 after purchasing an additional 10,925 shares in the last quarter. PVG Asset Management Corp lifted its holdings in Anavex Life Sciences by 503.5% during the 4th quarter. PVG Asset Management Corp now owns 78,490 shares of the biotechnology company’s stock valued at $843,000 after purchasing an additional 65,485 shares during the last quarter. Vermillion Wealth Management Inc. acquired a new position in Anavex Life Sciences in the fourth quarter valued at about $34,000. Finally, Squarepoint Ops LLC boosted its position in Anavex Life Sciences by 304.9% in the fourth quarter. Squarepoint Ops LLC now owns 67,627 shares of the biotechnology company’s stock valued at $726,000 after buying an additional 50,924 shares in the last quarter. Institutional investors and hedge funds own 31.55% of the company’s stock.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.